A double-blind, placebo-controlled trial of 2-dimethylaminoethanol was
undertaken in 27 patients with moderately severe or severe Alzheimer's
disease. Of 13 patients in the drug group, 6 were withdrawn in the first 5
weeks of the trial because of side effects, which included drowsiness and
retardation, with an increase of confusion and mild elevation of blood
pressure. No significant benefit appeared from the drug treatment.